Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 04, 2015 5:41 AM ET

Biotechnology

Company Overview of CytomX Therapeutics, Inc.

Company Overview

CytomX Therapeutics, Inc. operates as a biotechnology company that develops antibody therapeutics. It offers Probody therapeutics (immunotherapies and antibody drug conjugate therapies) for the treatment of cancer. CytomX Therapeutics, Inc. has strategic partnerships with Pfizer Inc., ImmunoGen, Inc., and Bristol-Myers Squibb. The company was founded in 2008 and is based in South San Francisco, California.

343 Oyster Point Boulevard

Suite 100

South San Francisco, CA 94080-1913

United States

Founded in 2008

Phone:

650-515-3185

Fax:

650-351-0353

Key Executives for CytomX Therapeutics, Inc.

Chief Executive Officer and Director
Age: 47
Co-Founder and Director
Age: 78
Founder and Member of Scientific Advisory Board
Consulting Chief Financial Officer
Age: 54
Chief Scientific Officer and Head of Research & Early Development
Age: 58
Compensation as of Fiscal Year 2014.

CytomX Therapeutics, Inc. Key Developments

CytomX Appoints Immuno-Oncology Leader Rachel Humphrey, M.D., to Board of Directors

CytomX announced the appointment of Rachel Humphrey, M.D., to its board of directors. Dr. Humphrey previously led immuno-oncology at AstraZeneca and prior to that was responsible for the clinical development of both Yervoy® (ipilmumab) at Bristol-Myers Squibb and Nexavar® (sorafenib) at Bayer. Dr. Humphrey recently served as senior vice president and head of immuno-oncology at AstraZeneca Pharmaceuticals. In this capacity, she was responsible for leading the therapeutic area's strategy and oversaw all aspects of the development of its PD-L1 inhibitor (MEDI4736), tremelimumab and the combination.

CytomX Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:00 PM

CytomX Therapeutics, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:00 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Sean A. McCarthy, Chief Executive Officer and Director.

CytomX Therapeutics Announces Executive Appointments

CytomX Therapeutics announced that it has appointed W. Michael Kavanaugh, M.D., as chief scientific officer and head of research and early development. In addition, the company has appointed Sridhar Viswanathan, Ph.D., as vice president of process sciences and manufacturing sciences and Danielle Olander as vice president of human resources. Prior to joining the company, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics. Since joining the company in 2009, he held multiple positions in research and development and led the growth of the company's therapeutic pipeline. Dr. Viswanathan joins the company from Perseid Therapeutics, where he served as vice president of process development and manufacturing operations. In this capacity, he was responsible for all internal process development and external manufacturing operations at contract manufacturing organizations for advancing CTLA4-Ig Fc fusion products for autoimmune disease and organ transplant rejection. Ms. Olander joined the company from Portola Pharmaceuticals where she served as the senior director of human resources management, leading all facets of human resources. This included the development of effective strategies that enabled Portola to thrive through periods of change, as well as supported short and long-term business objectives.

Similar Private Companies By Industry

Company Name Region
Breethe, Inc. United States
Worthington Biochemical Corporation United States
Replenish, Inc. United States
Protherics Inc. United States
Escape Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
February 11, 2015
--
Private Placement
December 22, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CytomX Therapeutics, Inc., please visit www.cytomx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.